Financials in USD. Standardized financial statements.
A compact view of how Pharma Mar, S.A. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $221.31M | $174.85M | $158.15M | $196.34M | $229.83M | $269.96M | $85.82M | $162.16M | $179.34M | $180.94M |
| Revenue Growth? | +26.6% | +10.6% | -19.5% | -14.6% | -14.9% | +214.6% | -47.1% | -9.6% | -0.9% | 0.0% |
| Cost of Revenue? | $12.26M | $8.18M | $9.61M | $13.64M | $16.44M | $13.72M | $5.23M | $35.87M | $45.67M | $43.97M |
| Gross Profit? | $209.05M | $166.67M | $148.54M | $182.70M | $213.39M | $256.24M | $80.59M | $126.30M | $133.67M | $136.97M |
| Gross Margin? | +94.5% | +95.3% | +93.9% | +93.1% | +92.8% | +94.9% | +93.9% | +77.9% | +74.5% | +75.7% |
| Operating Expenses? | $168.79M | $160.20M | $152.37M | $138.27M | $121.04M | $100.03M | $98.07M | $140.45M | $151.35M | $155.68M |
| Operating Income? | $40.26M | $6.47M | -$3.83M | $44.07M | $92.45M | $155.94M | -$17.48M | -$14.07M | -$17.68M | -$18.71M |
| EBITDA? | $48.28M | $21.23M | $4.55M | $52.07M | $104.08M | $155.94M | -$11.71M | -$9.47M | -$12.99M | -$12.24M |
| Income Before Tax | $59.63M | $11.98M | -$3.62M | $43.79M | $95.13M | $145.61M | -$21.65M | -$18.70M | -$22.86M | -$24.70M |
| Income Tax Expense | -$15.33M | -$14.14M | -$4.76M | -$5.57M | $2.27M | $8.34M | -$12.47M | -$2.50M | $3.90M | -$592,000 |
| Net Income? | $74.96M | $26.13M | $1.14M | $49.36M | $92.86M | $137.26M | -$9.18M | -$5.54M | -$26.75M | -$24.08M |
| EPS? | $4.36 | $1.49 | $0.06 | $2.73 | $5.14 | $7.50 | $-0.50 | $-0.30 | $-1.45 | $-1.31 |
| Diluted EPS? | $4.36 | $1.49 | $0.06 | $2.73 | $5.13 | $7.49 | $-0.50 | $-0.30 | $-1.45 | $-1.31 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality